10 Most Undervalued Biotech Stocks to Buy Now

2. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Forward P/E: 13.33

Number of Hedge Fund Holders: 59

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the top most undervalued biotech stocks to buy now. Analyst Joseph Schwartz from Leerink Partners reiterated a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on August 6, keeping the price target at $105.

The analyst told investors that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has promising pipeline developments and has exhibited solid financial performance. Its fiscal Q2 2025 sales of $825 million exceeded expectations, prompting an upward revision of the lower end of its full-year revenue guidance.

According to the analyst, these trends suggest robust demand, especially for the company’s product Voxzogo, which also surpassed sales expectations.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.